For the millions of patients who undergo surgery for non-small cell lung cancer each year, the question of what comes next — and whether adding immunotherapy to standard treatment can prevent recurrence — carries enormous stakes. A phase III randomized trial published in JAMA now offers a sobering answer for one widely used checkpoint inhibitor.
The trial evaluated whether nivolumab, a PD-1 inhibitor, administered as adjuvant therapy following surgical resection and completion of standard chemotherapy or radiotherapy improved outcomes in NSCLC patients. The study measured both disease-free survival (DFS) and overall survival (OS) as primary endpoints — two metrics that matter most to patients and oncologists alike. Despite the immunological rationale supporting post-surgical checkpoint blockade, nivolumab did not demonstrate a statistically significant improvement in either endpoint compared to observation alone across the enrolled cohort.
This finding is clinically important because it arrives in a crowded and rapidly shifting landscape. Atezolizumab and pembrolizumab have already earned FDA approval in adjuvant NSCLC settings, with pembrolizumab showing OS benefit in the PEARLS/KEYNOTE-091 trial. That nivolumab failed to replicate this pattern raises mechanistic questions: are PD-1 versus PD-L1 pathway distinctions meaningful post-resection, or do trial design differences — including chemotherapy completion requirements and patient selection by PD-L1 expression — account for divergent outcomes? The requirement that patients complete prior chemotherapy before randomization may have introduced selection bias toward more treatment-tolerant individuals, potentially limiting generalizability. This trial's null result also reinforces the emerging view that blanket immunotherapy escalation after curative-intent surgery is not automatically beneficial — patient stratification by tumor mutational burden or PD-L1 expression may be essential for identifying who actually benefits. For now, this represents an important corrective signal in a field prone to optimistic extrapolation.